TherapeuticsMD (TXMD) Non-Current Assets (2010 - 2026)

TherapeuticsMD (TXMD) has reported Non-Current Assets for 17 consecutive years, with $21.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 14.52% year-over-year to $21.4 million; the trailing twelve-month figure through Jun 2026 stood at $91.1 million (down 13.01% YoY), and the FY2025 full-year result was $23.2 million, down 12.62% from the prior year.
• Non-Current Assets retreated to $21.4 million in Q2 2026 per TXMD's latest filing, from $22.3 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $49.0 million in Q1 2022 and bottomed at $21.4 million in Q2 2026.
• Historically, Non-Current Assets has averaged $31.5 million across 5 years, with a median of $29.4 million in 2024.
• The widest YoY moves for Non-Current Assets: up 6.33% in 2022, down 29.79% in 2022.
• Over 5 years, Non-Current Assets stood at $35.1 million in 2022, then dropped by 10.24% to $31.5 million in 2023, then declined by 15.71% to $26.6 million in 2024, then slipped by 12.62% to $23.2 million in 2025, then decreased by 7.77% to $21.4 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $21.4 million, $22.3 million, and $23.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.